Featured
OpenAI Announces GPT-5.6: Sol, Terra and Luna for Production Workflows
OpenAI has announced GPT-5.6, a three-model family — Sol, Terra and Luna — built for production workflows in the API and Codex, alongside new token-efficiency features and a reframing of ChatGPT into Chat, Work and Codex. We walk through what is new, and why every performance claim, including the comparison to Claude Fable 5, should be read as a vendor benchmark.
Latest articles
View all →
pCloud for Small Business: A European Alternative to Google Workspace and OneDrive?
pCloud Business offers EU data residency, access levels, activity logs, branded links and 180-day history. Where it fits for a small firm — and where it doesn't.
Shopify Analytics Update: Metafields, Targets, Insights
Shopify upgraded its built-in analytics: slice reports by your own metafields, set targets on any metric, pin annotations onto charts and get automatic Insights on what's trending. What each addition does, why it kills a few spreadsheets, and where built-in analytics still hits its limits.
The AI Watchdogs Are Multiplying — and None of Them Are Talking to Each Other
A frontier lab, a national government, a central banker and a US state each moved to rein in AI within a single July week — and none was coordinating with the others. Oversight is finally arriving, but in disconnected pieces. That fragmentation is itself the story.
The AI Capex Squeeze: How GPU Spending Is Eating Enterprise IT Budgets
Corporate IT budgets barely grow year to year. So every dollar companies pour into scarce GPUs, AI servers and memory is a dollar pulled away from legacy software, licenses and mainframes. IBM's ~25% one-day crash is the clearest sign yet that the AI boom can hurt incumbent IT vendors before a model writes a single line of code.
AI-Designed Antibodies Move From Demo to the Pharma Supply Chain
AI models that design proteins and antibodies are compressing drug discovery's hardest step — and big pharma is paying to license them. Chai Discovery's $400M raise and its Pfizer, Lilly and Novartis deals show AI moving into the drug industry's real supply chain. But the clinical last mile still runs at old-world odds.
The Grid Wall: Why States Are Freezing AI Data Centers
The constraint on the AI buildout has shifted from chips to power. Aging grids can't absorb gigawatt-scale loads landing all at once — so New York just became the first US state to pause new data centers over 50 MW, and hyperscalers are pivoting to their own dedicated generation.